Effect of Ezetimibe on Gut Microbiota

Inclusion Criteria: * Age: 19 to 80 years old * Criteria for Diagnosis of Coronary Artery Disease: Patients diagnosed with coronary artery disease through coronary angiography, or Patients who require high-intensity lipid-lowering therapy according to current guidelines: Clinical atherosclerotic cardiovascular disease, LDL cholesterol ≥ 190 mg/dL, LDL 70-189 mg/dL in diabetic patients, 10-year calculated atherosclerotic cardiovascular disease risk ≥ 7.5% \- Voluntary Consent: Individuals who have voluntarily agreed to participate in the study and signed the consent form. Exclusion Criteria: * Patients with active liver disease or liver disease with AST/ALT levels elevated more than twice the upper limit of normal. * Individuals with allergies or hypersensitivity to HMG-CoA reductase inhibitors or ezetimibe. * Individuals with a history of adverse reactions to HMG-CoA reductase inhibitors or ezetimibe. * Pregnant, breastfeeding, or women of childbearing potential. * Organ transplant recipients or individuals scheduled for organ transplantation. * Patients with active malignant tumors. * Patients with inflammatory bowel disease. * Patients with wasting diseases, autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis), or connective tissue diseases (e.g., systemic sclerosis, polymyositis, and dermatomyositis). * Patients with a history of taking antibiotics, probiotics, or ezetimibe within 3 months prior to study screening. * Patients who have undergone gastrointestinal surgery within the past year. * Patients who do not understand the study content or are unable to provide consent.